To identify overall and site-specific rates of nosocomial infections (NIs) during the neutropenic, as compared to the non-neutropenic stage of treatment in adult recipients of allogeneic and autologous bone marrow transplantation (BMT) and peripheral blood stem-cell transplantation (PBSCT), a prospective, 54-month study was started at the Haematological Stem Cell Transplantation Unit of the University Hospital of Freiburg, Germany. NI types were identified using modified CDC definitions. A total of 351 patients (14 256 in-patient days, 5026 neutropenic days) were investigated (316/90% allogeneic, 35/10% autologous; BMT: 119 patients, PBSCT: 234 patients). The mean length of neutropenia was 14.3 days (range: 0-66). Antimicrobial prophylaxis for allogeneic transplantation consisted of ciprofloxacin, trimethoprim/sulphamethoxazole, fluconazole, and metronidazole. In total, 239 NIs were identified in 169 patients (48.1%), and of these 171 (71.5%) occurred during neutropenia (34.0 NIs per 1000 days at risk). The main pathogens were coagulase-negative staphylococci (36.3%), Clostridium difficile (20.4%), and enterococci (10.0%). Site-specific incidence densities during neutropenia vs non-neutropenia were: 13.9 vs 1.6 bloodstream infections (all central lineassociated), 11.9 vs 1.8 pneumonias, 3.0 vs 2.9 gastroenteritis, and 1.6 vs 0.3 urinary tract infections. The greatest number of NI in BMT and PBSCT recipients is acquired during neutropenia, and multicentre surveillance programmes should focus on this.
tion; PBSCT; surveillance The high incidence of nosocomial infection (NI) is a common problem in patients with haematological malignancies, especially because of the severity of illness of the patients treated and the advanced therapies implemented that regularly lead to severe immunosuppression. 1, 2 Today's hospital infection control initiatives include surveillance as a programme involving the systematic collection, tabulation, analysis, and feedback of data on the occurrence of NI. Data useful for identifying patients who are infected, for determining the site of infection, and for identifying factors that contribute to the incidence of NI are available. [3] [4] [5] [6] NI rates mainly depend on the severity of illness of the patients treated, on therapeutic interventions (eg immunosuppressive therapy), and on exposure to invasive devices or procedures (especially ventilator use, central venous catheters (CVCs), urinary catheters). 7 In addition, after allogeneic and autologous bone marrow transplantation (BMT) or peripheral blood stem-cell transplantation (PBSCT), patients are at particular risk of acquiring one or more NIs, especially during the neutropenic phase of their therapeutic course. Unlike the situation prevailing in other medical settings, reference data on the incidence of NIs in these patients are not available. However, information on special aspects has been provided by several authors, 1, 2, [8] [9] [10] [11] [12] [13] and Marena et al 14 recently published data on the incidence of NI among 143 adult and paediatric haematopoietic stem-cell transplantation (HSCT) recipients.
To assess the incidence of NI, to identify overall and sitespecific infection rates, and to improve the quality of care in our institution, in November 1996 a prospective study was started at the Adult HSCT-Unit of the University Hospital of Freiburg, Germany (UHF; 1700 beds, 52 940 patients admitted in 1999 giving a total of 485 470 in-patient days). The study was part of the nosocomial surveillance programme of the German National Reference Centre for Hospital Hygiene.
Patients and methods

Ward and study population
This prospective study was carried out at the HSCT unit of the Department of Haematology/Oncology of the UHF, which until September 1999 had eight beds and later 14 beds. The unit is a referral centre serving approx 1.5 million people in Southwest Germany. In keeping with the general situation at HSCT units in Germany, the main primary diagnoses of patients with haematological malignancies include acute myelogenous leukaemia (AML), chronic myelogenous leukaemia (CML), and acute lymphoid leukaemia (ALL) for allogeneic transplantation. 15 Following a 3-month training period, from February 1997 to July 2001, the data of 351 patients were collected. All HSCT therapies were performed in rooms with high-efficiency particulate air (HEPA) filters. In addition, patients with allogeneic transplantation were nursed in single rooms.
Surveillance
A trained and experienced infection control practitioner (RB) visited the ward once a week in the morning. General data collected included name, age, sex, diagnosis, type of central venous catheter, and antimicrobial/antineoplastic treatment. Nursing notes, medical notes, microbiology reports, temperature charts, and antibiotic treatment charts were reviewed to determine if a patient had any signs or symptoms of infection. In addition, the nursing and medical staff were consulted about any queries regarding signs and symptoms. Since almost no urinary catheters were used on the patients, the number of device days was only recorded for central line-days.
The infection control nurse filled out a worksheet for every patient (infected and not infected) and once a week these worksheets were reviewed by a physician trained in infection control. A special post-discharge follow-up was not carried out. Further details on the surveillance method used have been described by Emmerson and Perl. 3, 16 In addition to surveillance with this reference method, the time required for data collection and analysis was assessed.
Definitions
Infections occurring during the study period were categorised by specific infection site according to standard CDC definitions that include clinical and laboratory criteria. 17, 6 However, a few modifications were implemented because of the absence of clinical manifestations of focal infection and leucocyte response as proposed and described in detail by Carlisle et al. 2 In line with these definitions, the following criteria were taken into account for the diagnosis of nosocomial pneumonia:
Fever and new or worsening infiltrate (chest radiograph, if necessary thoracic CT). Fulfilment of at least two of the following criteria: production of sputum, cough, dyspnoea, rhonchi or rales, polymorphonuclear leucocytes on sputum Gram stain, pleural rub. In cases of suspected invasive aspergillosis, serological tests to identify aspergilli (latex agglutination test for the detection of circulating aspergillus galactomannan); additionally, demonstration of aspergilli in the sputum and thoracic CT.
During neutropenia, the latex agglutination test was performed once a week.
Bloodstream infections (BSI) were defined as follows:
Recognised pathogen isolated from one or more blood cultures and fever or shock. Common skin contaminant isolated from two separate blood cultures and fever. Common skin contaminant isolated from one blood culture in a patient with an intravascular device, fever, and physician's diagnosis. Common skin contaminant isolated from one blood culture and diagnosis by the physician of septic shock. A BSI was defined as device-associated (lineassociated) if there was no sign of infection at another site. Catheter-associated infections (CAI) ( ¼ skin/soft tissue infection at the catheter insertion site or at a distance of 2 cm in the case of tunnelled catheters) were defined as follows: Purulent drainage, pustules, vesicles, or boils. Localised pain/tenderness and redness with exudate, fluctuance, ulceration, or fever. Positive culture from aspiration, biopsy, or surgical incision and drainage, and physician diagnosis.
Infections occurring at more than one site in the same patient were reported as separate infections with the exception of secondary BSI caused by pneumonia. Classification of an infection as nosocomial was only possible if there was no evidence showing that it had been present or in incubation at the time of admission to the ward.
Neutropenia was defined as an absolute white blood cell count (WBC) o1 Â 10 9 /l.
Statistics
Device utilisation ratios (central lines) and site-specific incidence densities per 1000 days at risk (neutropenia and central line, respectively) or per 1000 patient days were calculated (see Figure 1 ). 7 A Poisson model was applied for comparison of central line-associated infections in patients receiving a CVC vs patients with a Hickman catheter. 18 
Results
Over the 54-month period, the 351 patients accounted for 14 256 in-patient days, of which 5026 were neutropenic Device utilisation ratio ðDUÞ ¼ number of device days number of patient days
Risk-associated ðdevice-associatedÞ infection rates ¼ number of ðdevice-associatedÞ infections for a specific siteÂ1000 number of days at risk ðdevice-daysÞ Figure 1 Formula used for calculation of device utilisation ratios and risk-associated (device-associated) infection rates.
days. Of these patients, 316 (90%) had undergone allogeneic HSCT and 35 (10%) autologous HSCT (BMT: 119 patients, PBSCT: 234 patients, two patients underwent both); 141 patients were women and 210 were men. The mean age was 42.6 years (range: ) and the mean length of stay in the HSCTU was 40.6 days (range: 14-112), 14.3 days thereof during neutropenia (range: 0-66). The primary diagnoses are shown in Table 1 . Antimicrobial prophylaxis consisted of oral ciprofloxacin, trimethoprim/sulphamethoxazole (till day À2, and again after reconstitution), fluconazole, and (in a subset) metronidazole for patients receiving allogeneic transplantation from the beginning of conditioning treatment until engraftment. With the exception of the oral amphotericin, selective antimicrobial decontamination of the gut (by means of nonadsorbable agents) was not performed.
We found 19 Gram-negative infections (Table 5) . Of these, 18 were identified in patients undergoing allogeneic HSCT, who were receiving ciprofloxacin prophylaxis. Six of the 18 isolates were ciprofloxacin resistant, 12 were sensitive. The vast majority of the resistant agents were Escherichia coli (five of six). Of nine E. coli isolates, five were resistant. A total of 15 yeasts isolates were identified in 13 patients, of whom 11 had received allogeneic HSCT and fluconazole prophylaxis; 12 yeast isolates were found in these 11 patients. Two of nine isolates tested were fluconazole-resistant (both c krusei).
Device utilisation/NIs
During the study period, 13 088 central line-days were recorded (10 413 CVC-days, 2675 days with a Hickman catheter). The ratios for central line utilisation are shown in Table 2 . None of the catheters was coated with antimicrobial substances.
A total of 239 NIs were identified in 169 patients (120 patients with one, 33 patients with two, 14 patients with three, and one patient each with four and seven NIs, respectively); this corresponds to an infection rate of 68.1 per 100 patients and an incidence density of 16.8/1000 patient days. Of these infections, 171 (71.5%) were identified in 132 patients during neutropenia, with 34.0 NIs per 1000 days at risk. Table 3 shows the site-specific incidence rates (NIs/100 patients) and incidence densities (NIs/1000 days at risk). All BSIs were device-related, and compared with Hickman catheters, the difference observed in the incidence density of central line-associated BSI for CVCs was small (6.3 vs 7.1 BSI per 1000 patient days; see Table 3 ). Thus, any assumption of different rates cannot be confirmed.
The time required to collect data in the HSCTU using the surveillance method described above, to document, and to analyse these data was given as 420 min per week (14 beds), a figure that corresponds to 5 h per 10 beds per week.
The primary diagnoses of patients with one or more NIs were mainly AML, CML, and ALL (Table 4) . Phlegmon of the orbita, folliculitis, sinusitis maxillaris, brain abscess.
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Microbiology
As shown in Table 5 in descending order of frequency and related to the site-specific infections, a total of 201 pathogenic microorganisms were isolated. In 69 (during neutropenia: 52) cases of NI, no pathogen could be isolated: pneumonia, 59 (45); CAI, 6 (5); others, 4 (2).
Discussion
During the last decades, allo-and auto-HSCT have gained immense importance in the therapeutic management of haematology patients. [19] [20] [21] [22] [23] [24] Apart from reports about NI outbreaks, [25] [26] [27] [28] information on the endemic occurrence of NI in these patients is limited. 2, [12] [13] [14] 29 Therefore, a prospective study was initiated to assess more detailed data on the incidence of NI in an adult HSCT-unit and to use them as a basis for improving quality of care at our institution.
The incidence density of NI during the neutropenic state documented in the present study ( 14 and our data. However, Hickman catheters were used only in a minority of our patients (Table 3) .
The topic of bacterial pneumonia in HSCT patients has been addressed by few investigators. In 255 allogeneic and AML  59  88  32  27  5  18  3  3  CML  27  37  15  10  3  5  3  1  ALL  25  38  11  11  5  8  3  0  MDS  16  21  8  7  1  4  1  0  NHL  15  18  4  9  2  3  0  0  Others   a   27  37  15  13  4  4  1  0 a One patient with BSI and pneumonia had both AML and ALL. autologous BMT recipients, 15% experienced 52 episodes of pneumonia. Of these, 13 occurred within 30 days of transplantation and hospital-acquired Gram-negative bacteria predominated. 34 The criteria used to define nosocomial pneumonia differ from those used in our investigation (ie, pulmonary infiltrate and fever must always be present) and it should be kept in mind that new NI definitions are being discussed for pneumonia.
In contrast to all other site-specific NI, the incidence density of gastroenteritis associated with C. difficile was documented in equal magnitude during neutropenia and the non-neutropenic phase. This is likely to be a consequence of the intensive use of antibiotics and antineoplastic chemotherapy. In one retrospective study, Chakrabarti et al 35 documented that 13% of the 75 allogeneic HSCT recipients acquired C. difficile infection, a figure comparable to our results. As Hanna et al 25 point out, ongoing surveillance is helpful in detecting small outbreaks in a timely fashion.
As regards intensive care therapy, the most important database documenting the occurrence of NI is provided by the US National Nosocomial Infections Surveillance' System (NNIS). 7 However, as no information regarding HSCT is provided, data representing the medical ICU setting (more than 120 units with a total of 1 062 909 patient days from 1995 to 2000) can, with a degree of caution, be used for comparison. A high overall incidence (71.4%) and a moderate incidence density (17.7/1000 patient days) of NI in patients treated at the HSCT unit of the UHF was documented. As against data for medical ICUs reported by NNIS, the central line-associated infection rate during neutropenia (14.8 BSI/1000 days at risk, Table 3 ) lay well above the 90% percentile (9.8). 7 In comparison, our finding of 1.7 BSI/1000 non-neutropenic days lay below the 10% percentile (2.0).
The dominance of Gram-positive microbial isolates at the top of the list (coagulase-negative staphylococci (36%), C. difficile (20%), enterococci (10%), streptococci (7.4%)) as well as yeasts (7.4%) (Table 5 ) confirms the results of two studies by Marena et al (64%) 14 and Collin et al 36 (69% in 1991, declining to 56% in the 1996-1997 period).
The proportion of ciprofloxacin-resistant Gram-negative agents was remarkably high, especially E. coli. This could be because of widespread prophylactic use of ciprofloxacin in allogeneic HSCT recipients. Despite fluconazole-prophylaxis, resistance among yeasts to this antimycotic drug does not seem to be an emerging problem.
The small number of viral infections (three pneumonias and one gastroenteritis) documented in this study may partly be explained by the fact that no postdischarge surveillance was performed. La Rosa et al 37 state that in cases of adenovirus infection, the mean time to diagnosis was 155 days, a higher figure than the maximum length of stay in our HSCTU (112 days).
After HSCT, invasive fungal infections (IFI) have become a leading cause of infectious mortality. In order to analyse the incidence and risk factors for IFI following allogeneic BMT, Jantunen et al 38 retrospectively analysed 142 patients and documented 15 cases (11%) with definite or probable invasive aspergillosis. The median time to diagnosis was 136 days after BMT. As with viral infections, again this is a figure higher than the maximum length of stay in our investigation, a fact influencing our comparatively low figure of 1.4% for invasive aspergillosis ( ¼ five infections with aspergilli in 351 patients: three cases of pneumonia, one patient with brain abscesses, one patient with maxillary sinusitis). All patients with invasive aspergillosis had undergone allogeneic HSCT.
One limitation of our study is the fact that no postdischarge follow-up was performed, which may have led to under-reporting, especially in the case of viral and fungal infections. However, patients were discharged from the HSCT unit only 3-4 weeks after stable engraftment, which in turn resulted in a much lower risk of NI occurring after leaving the unit. The majority of patients developing an NI shortly after discharge from the unit were transferred back to the unit to control this infection, which was later categorised as nosocomial.
As a result of the relatively high number of allogeneic HSCT, we did not differentiate from results with autologous HSCT, expecting a higher rate of NI as described in the literature for patients undergoing allogeneic vs autologous HSCT. 11 This may be owing to the immunosuppressive therapy in allogeneic HSCT. A subanalysis of this will form part of our future work.
As previously pointed out, our surveillance activities formed part of infection control efforts to improve the quality of care at our institution. According to the 'Study on the Efficacy of Nosocomial Infection Control' (SENIC), well-organised surveillance and control activities, an adequate number of trained infection control staff, and the reporting of infection rates to medical staff are essential for NI control programmes to be effective. 39 However, because of restricted resources, in clinical practice, total surveillance of NI should be replaced by surveillance systems targeted to specific outcome objectives. 3 With the reference surveillance method used in this study, the time required for data collection in the BMTU and for data analysis (5 h per 10 beds per week) was in the range of that required for surveillance in a neurology intensive-care unit (3.4 h), but approximately four times higher than a selective surveillance method. 40 Since data collection is very timeconsuming, such selective methods, for example, ones that focus on the neutropenic state of patients with haematological malignancies, those are necessary for infection control teams to operate on a daily basis and to optimise cost effectiveness. 4 In line with prior experience and study findings, our data add to the strong evidence that the greatest number of NIs in HSCT patients are acquired during neutropenia. Evidence-based infection control strategies for HSCT recipients have recently been compiled and published by the CDC in collaboration with the IDSA, and the ASBTM. 41 During the study period, the surveillance activities also led to an increase in infection control measures on the wards. To consequently prevent NI in this patient population, and to improve and assure the quality of care with respect to the highly sophisticated therapeutic regimens applied, reference data regarding the occurrence of these infections should, in future, be made available. The German National Reference Centre for Surveillance of Nosocomial Infection recently launched a national pilot project to systematically survey NI occurring in HSCT patients during neutropenia.
The preliminary results of this study were presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy', Toronto, 17-20 September, 2000.
